Collectively, these findings reveal that glycolysis‐related ROS regulate the CSC and EMT phenotypes by targeting DCLK1 in GR cells, suggesting that DCLK1 is a promising target in treating pancreatic cancer. This evidence concerns the gene DCLK1 and pancreatic neoplasm.